Rahmer Peter 4

What Happened

• Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 753 shares in an open-market/private sale on April 28, 2026, at $14.79 per share, yielding $11,137. The sale was executed to cover income tax withholding obligations arising from the vesting of restricted stock units (RSUs).

Key Details

• Transaction date and price: 4/28/2026 — 753 shares @ $14.79 (total $11,137) (Transaction code: S — Sale)
• Reason/footnote: Sale was to satisfy income tax withholding on 3,051 RSUs that vested on 4/27/2026; the reporting person had no discretion over the sale and it was done per the issuer's RSU vesting policies (footnote F1).
• Holdings note: Filing indicates 9,153 shares underlying RSUs are included in holdings per footnote F2.
• Filing timeliness: Form 4 filed 4/30/2026 for a 4/28/2026 transaction — appears timely (not marked late).

Context

• This was a routine, non-discretionary sale to cover tax obligations on vested RSUs, not an open-market purchase or a discretionary sell signal. Such withholding sales are common following equity vesting and do not necessarily indicate the insider’s view on the company’s prospects.